Frederick Ofosu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4768070/publications.pdf

Version: 2024-02-01

35 papers	1,230 citations	361296 20 h-index	414303 32 g-index
35 all docs	35 docs citations	35 times ranked	555 citing authors

#	Article	IF	Citations
1	An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes. Thrombosis Research, 2015, 136, 1053-1054.	0.8	0
2	Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins. Thrombosis and Haemostasis, 2008, 99, 874-882.	1.8	52
3	Current use of biologicals in thrombosis and haemostasis. Thrombosis and Haemostasis, 2008, 99, 805-806.	1.8	0
4	Propagating factor IX-producing hepatocytes for haemophilia B therapy. Thrombosis and Haemostasis, 2008, 99, 799-800.	1.8	5
5	Differences in the safety profiles of two low-molecular-weight heparins. Thrombosis and Haemostasis, 2008, 99, 989-990.	1.8	3
6	Altered regulation of in-vivo coagulation in orthopedic patients prior to knee or hip replacement surgery. Blood Coagulation and Fibrinolysis, 2007, 18, 219-225.	0.5	11
7	Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment. Thrombosis and Haemostasis, 2006, 96, 568-577.	1.8	9
8	Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thrombosis and Haemostasis, 2005, 94, 958-964.	1.8	130
9	Thrombin and Antithrombotics. Seminars in Thrombosis and Hemostasis, 1998, 24, 87-91.	1.5	66
10	Pharmacological Actions of Sulodexide. Seminars in Thrombosis and Hemostasis, 1998, 24, 127-138.	1.5	56
11	Plasmin accelerates plateletâ€dependent prothrombinase formation without activating the platelets. British Journal of Haematology, 1996, 92, 458-465.	1.2	5
12	Control Mechanisms in Thrombin Generation. Seminars in Thrombosis and Hemostasis, 1996, 22, 303-308.	1.5	30
13	Anticoagulant Actions of Tissue Factor Pathway Inhibitor on Tissue-Factor-Dependent Plasma Coagulation. Seminars in Thrombosis and Hemostasis, 1995, 21, 240-244.	1.5	8
14	Prolonged Antithrombin Activity of Low-Molecular-Weight Heparins. Circulation, 1995, 92, 2819-2824.	1.6	32
15	Thrombin Regulation in Children Differs from Adults in the Absence and Presence of Heparin. Thrombosis and Haemostasis, 1994, 72, 836-842.	1.8	114
16	Hemostatic System Activation in Patients with Lupus Anticoagulant and Essential Thrombocythemia. Seminars in Thrombosis and Hemostasis, 1994, 20, 324-327.	1.5	16
17	Thrombin Regulation in Mother and Fetus During Pregnancy. Seminars in Thrombosis and Hemostasis, 1992, 18, 81-90.	1.5	48
18	Effects of Dermatan Sulfate and Heparin on Inhibition of Thrombus Growth in Vivo. Annals of the New York Academy of Sciences, 1989, 556, 304-312.	1.8	34

#	Article	IF	Citations
19	Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thrombosis Research, 1988, 52, 517-527.	0.8	63
20	Transfusion-Induced Specific Antiâ€“Factor XI Inhibitor in a Patient with Previously Unrecognized Factor XI Deficiency. American Journal of Clinical Pathology, 1988, 89, 418-422.	0.4	15
21	Mechanisms of Action of Heparin: Applications to the Development of Derivatives of Heparin and Heparinoids with Antithrombotic Properties. Seminars in Thrombosis and Hemostasis, 1988, 14, 9-17.	1.5	21
22	Evolution of Thrombosis. Annals of the New York Academy of Sciences, 1987, 516, 586-604.	1.8	10
23	Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thrombosis Research, 1986, 43, 491-495.	0.8	139
24	The haemorrhagic and antithrombotic effects of dermatan sulphate. British Journal of Haematology, 1986, 64, 309-317.	1.2	87
25	Lack of Relationship Between Enhanced Bleeding Induced by Heparin and Other Sulfated Polysaccharides and Enhanced Catalysis of Thrombin Inhibition. Seminars in Thrombosis and Hemostasis, 1986, 12, 324-327.	1.5	12
26	Rationale Behind the Development of Low Molecular Weight Heparin Derivatives. Seminars in Thrombosis and Hemostasis, 1985, 11, 13-16.	1.5	41
27	Heparin Cofactor II and Other Endogenous Factors in the Mediation of the Antithrombotic and Anticoagulant Effects of Heparin and Dermatan Sulfate. Seminars in Thrombosis and Hemostasis, 1985, 11, 133-137.	1.5	25
28	Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth. Thrombosis Research, 1985, 40, 81-89.	0.8	57
29	Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III. Canadian Journal of Biochemistry and Cell Biology, 1984, 62, 975-983.	1.3	11
30	Perspectives on the Role of Platelets in Hemostasis and Thrombosis. , 1984, , 115-126.		0
31	Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thrombosis Research, 1982, 28, 487-497.	0.8	35
32	Activation of factor X and prothrombin in antithrombin-III depleted plasma: The effects of heparin. Thrombosis Research, 1981, 23, 331-345.	0.8	25
33	The factor VIII-independent activation of factor X by factors IXa and VII in plasma. Thrombosis Research, 1981, 21, 23-33.	0.8	5
34	Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography. Thrombosis Research, 1980, 20, 77-83.	0.8	20
35	The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III. Thrombosis Research, 1980, 20, 391-403.	0.8	45